Type : | Industriel |
Statut : | Ouvert |
Phase : | III |
Étape du traitement : | Traitements combinés |
Date d'ouverture : | 04/07/2022 |
Date clôture : | 30/09/2032 |
Promoteur : | Hoffmann-La Roche |
Progression du cancer: | Loco-régional et à distance |
Résumé :
This Phase III, randomized, two-arm, open-label, multicenter study will evaluate the efficacy and safety of giredestrant plus Phesgo compared with Phesgo after induction therapy with Phesgo plus taxane in participants with human epidermal growth factor receptor 2 (HER2)-positive, estrogen receptor (ER)-positive advanced breast cancer (metastatic or locally advanced disease not amenable to curative treatment) who have not previously received a systemic non-hormonal anti-cancer therapy in the advanced setting.
Domaines/spécialités :
- Cancer du sein
Biomarqueurs :
- HER2
- ER
Pathologies :
- Tumeur maligne du sein - Cim10 : C50
Liens externes :